2. Search Result
Search Result
Results for "

Prostatic hyperplasia

" in MedChemExpress (MCE) Product Catalog:

81

Inhibitors & Agonists

1

Biochemical Assay Reagents

4

Peptides

10

Natural
Products

13

Isotope-Labeled Compounds

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-13635
    Finasteride
    4 Publications Verification

    MK-906

    		 Environmental Pollutants 5 alpha Reductase Cancer
    Finasteride (MK-906) is an orally active and competitive 5α-reductase inhibitor, with an IC50 of 4.2 nM for type II 5α-reductase. Finasteride has approximately a 100-fold greater affinity for type II 5α-reductase enzyme than for the type I enzyme. Finasteride can be used for the research of benign prostatic hyperplasia (BPH) and androgenic alopecia .
    Finasteride
  • HY-B0661
    Tamsulosin
    2 Publications Verification

    (R)-(-)-YM12617 free base; LY253351 free base

    		 Adrenergic Receptor Apoptosis Neurological Disease Endocrinology Cancer
    Tamsulosin ((R)-(-)-YM12617 free base) is an orally active antagonist of α1-adrenergic receptor. Tamsulosin induces Apoptosis. Tamsulosin is used for the research of prostatic hyperplasia. Tamsulosin attenuates abdominal aortic aneurysm growth and inhibits inflammation in animal models .
    Tamsulosin
  • HY-B0371F
    Terazosin hydrochloride
    Maximum Cited Publications
    7 Publications Verification

    		 Adrenergic Receptor Cardiovascular Disease Metabolic Disease Endocrinology
    Terazosin hydrochloride is a quinazoline derivative and a competitive and orally active α1-adrenoceptor antagonist. Terazosin hydrochloride works by relaxing blood vessels and the opening of the bladder. Terazosin hydrochloride has the potential for benign prostatic hyperplasia (BPH) and high blood pressure treatment .
    Terazosin hydrochloride
  • HY-10122
    Silodosin
    5 Publications Verification

    KAD 3213; KMD 3213

    		 Adrenergic Receptor Bacterial Endocrinology Cancer
    Silodosin (KAD 3213; KMD 3213) is a potent, selective and orally active α1A-adrenergic receptor (α1A-AR) blocker. Silodosin exhibits high affinity for α1A-AR (Ki=0.036 nM), over 162-fold and 50-fold than for α1B-AR and α1D-AR with Ki values of 21 nM and 2.0 nM, respectively. Silodosin is an effective and well-tolerated agent, it can be used for the investigation of LUTS/BPH .
    Silodosin
  • HY-B0304A
    Dapoxetine hydrochloride
    1 Publications Verification

    LY-210448 hydrochloride

    		 Serotonin Transporter Neurological Disease
    Dapoxetine (LY-210448) hydrochloride is an orally active and selective serotonin reuptake inhibitor (SSRI). Dapoxetine hydrochloride can be used for the research of premature ejaculation (PE) .
    Dapoxetine hydrochloride
  • HY-B0661A
    Tamsulosin hydrochloride
    2 Publications Verification

    (R)-(-)-YM12617; LY253351

    		 Adrenergic Receptor Apoptosis Neurological Disease Endocrinology Cancer
    Tamsulosin hydrochloride ((R)-(-)-YM12617 free base) is an orally active antagonist of α1-adrenergic receptor. Tamsulosin hydrochloride induces Apoptosis. Tamsulosin hydrochloride is used for the research of prostatic hyperplasia. Tamsulosin hydrochloride attenuates abdominal aortic aneurysm growth and inhibits inflammation in animal models .
    Tamsulosin hydrochloride
  • HY-B0192
    Alfuzosin
    1 Publications Verification

    SL 77499

    		 Adrenergic Receptor Endocrinology
    Alfuzosin (SL 77499-10) is an orally active, selective and competitive α1-adrenoceptor antagonist. Alfuzosin relaxes the muscles of the prostate and bladder neck, aiding in urination. Alfuzosin can be used in study of benign prostatic hyperplasia (BPH) .
    Alfuzosin
  • HY-B0391
    Naftopidil
    1 Publications Verification

    KT-611; BM-15275

    		 Adrenergic Receptor Cardiovascular Disease Endocrinology
    Naftopidil (KT-611) is is a selective alpha1-adrenoceptor antagonist, with Kis of 3.7 nM, 20 nM and 1.2 nM for the cloned human α1a-, α1b- and α1d-adrenoceptor subtypes, respectively. Naftopidil has antiproliferative effects. Naftopidil can be used for the research of prostate hyperplasia .
    Naftopidil
  • HY-B0371
    Terazosin
    Maximum Cited Publications
    7 Publications Verification

    		 Adrenergic Receptor Cardiovascular Disease Metabolic Disease Endocrinology
    Terazosin is a quinazoline derivative and a competitive and orally active α1-adrenoceptor antagonist. Terazosin works by relaxing blood vessels and the opening of the bladder. Terazosin has the potential for benign prostatic hyperplasia (BPH) and high blood pressure treatment .
    Terazosin
  • HY-B0371A
    Terazosin hydrochloride dihydrate
    Maximum Cited Publications
    7 Publications Verification

    		 Adrenergic Receptor Cardiovascular Disease Metabolic Disease Endocrinology
    Terazosin hydrochloride dihydrate is a quinazoline derivative and a competitive and orally active α1-adrenoceptor antagonist. Terazosin hydrochloride dihydrate works by relaxing blood vessels and the opening of the bladder. Terazosin hydrochloride dihydrate has the potential for benign prostatic hyperplasia (BPH) and high blood pressure treatment .
    Terazosin hydrochloride dihydrate
  • HY-107385
    Epristeride
    3 Publications Verification

    ONO-9302; SKF105657

    		 5 alpha Reductase Cancer
    Epristeride (ONO-9302) is a selective, specific and orally active uncompetitive inhibitor of human steroid 5 alpha-reductase isoform 2. Epristeride has inhibitory effects for SR isoenzymes types 2 with Ki value of 0.7-2 nM. Epristeride can be used for the research of prostatic hyperplasia and acne .
    Epristeride
  • HY-B0192A
    Alfuzosin hydrochloride
    1 Publications Verification

    SL 77499-10

    		 Adrenergic Receptor Endocrinology
    Alfuzosin (SL 77499-10) hydrochloride is an orally active, selective and competitive α1-adrenoceptor antagonist. Alfuzosin hydrochloride relaxes the muscles of the prostate and bladder neck, aiding in urination. Alfuzosin hydrochloride can be used in study of benign prostatic hyperplasia (BPH) .
    Alfuzosin hydrochloride
  • HY-115450
    ONO-0300302

    		LPL Receptor Endocrinology Cancer
    ONO-0300302 is an orally active and potent LPA1 (lysophosphatidic acid receptor 1) antagonist, with an IC50 of 0.086 μM. ONO-0300302 is a slow tight binding inhibitor, and its binding affinity increases with time, with Kd of 0.34 nM (37 °C, 2 h). ONO-0300302 can be used for benign prostatic hyperplasia (BPH) research .
    ONO-0300302
  • HY-158498
    FA2 glycan (G0F)

    FA2 N-linked oligosaccharide; F(6)A2 glycan

    		 Biochemical Assay Reagents Cancer
    FA2 glycan (G0F) (FA2 N-linked oligosaccharide; F(6)A2 glycan) is a core-fucosylated biantennary N-linked oligosaccharide that serves as a prostate cancer biomarker. The level of FA2 glycan (G0F) is higher in prostate cancer than in benign prostatic hyperplasia, and it is further elevated in advanced prostate cancer with a Gleason score ≥8 compared with both benign prostatic hyperplasia and low-/intermediate-risk prostate cancer. FA2 glycan (G0F) can be used in prostate cancer research .
    FA2 glycan (G0F)
  • HY-P3501
    Fexapotide

    NX-1207

    		 Apoptosis Cancer
    Fexapotide (NX-1207) induces apoptosis selectively, reducing prostate volume at a cellular level. Fexapotide can be used in lower urinary tract symptoms (LUTS) and benign prostatic hyperplasia (BPH) research .
    Fexapotide
  • HY-103204
    RS100329 hydrochloride

    		Adrenergic Receptor Endocrinology
    RS100329 hydrochloride is a potent and selective α1A-adrenoceptor antagonist with pKi values of 9.6, 7.9 and 7.5 for α1A, α1D, and α1B, respectively. RS100329 hydrochloride inhibits reflex urethral contractions. RS100329 hydrochloride can be used in research of benign prostatic hyperplasia .
    RS100329 hydrochloride
  • HY-B0304
    Dapoxetine

    (S)-(+)-Dapoxetine; LY-210448

    		 Serotonin Transporter Neurological Disease
    Dapoxetine (LY-210448) is an orally active and selective serotonin reuptake inhibitor (SSRI). Dapoxetine can be used for the research of premature ejaculation (PE) .
    Dapoxetine
  • HY-N8850
    Angelol G

    		Others Cancer
    Angelol G, a coumarin, can be isolated from Campylotropis hirtella. Angelol G shows inhibitory activity for prostate specific antigen (PSA)IC50 value of 152.1μM. Angelol G can be used for the research of benign prostate hyperplasia (BPH) .
    Angelol G
  • HY-13635A
    Finasteride acetate

    MK-906 acetate

    		 5 alpha Reductase Cancer
    Finasteride (MK-906) acetate is a potent and competitive 5α-reductase inhibitor, with an IC50 of 4.2 nM for type II 5α-reductase. Finasteride acetate has approximately a 100-fold greater affinity for type II 5α-reductase enzyme than for the type I enzyme. Finasteride acetate can be used for the research of benign prostatic hyperplasia (BPH) and androgenic alopecia .
    Finasteride acetate
  • HY-12718
    (±)-WB 4101

    		Adrenergic Receptor Cardiovascular Disease
    (±)-WB 4101 is a highly selective α1-adrenergic receptor antagonist. (±)-WB 4101 blocks norepinephrine-induced vascular smooth muscle contraction to exert antihypertensive and benign prostatic hyperplasia (BPH)-relieving effects. (±)-WB 4101 is promising for research of hypertension and BPH .
    (±)-WB 4101
  • HY-B0371S
    Terazosin-d8

    		Isotope-Labeled Compounds Adrenergic Receptor Metabolic Disease Endocrinology
    Terazosin-d8 is deuterium labeled Terazosin. Terazosin is a quinazoline derivative and a competitive and orally active α1-adrenoceptor antagonist. Terazosin works by relaxing blood vessels and the opening of the bladder. Terazosin has the potential for benign prostatic hyperplasia (BPH) and high blood pressure treatment .
    Terazosin-d8
  • HY-13635R
    Finasteride (Standard)

    MK-906 (Standard)

    		 Reference Standards 5 alpha Reductase Cancer
    Finasteride (Standard) is the analytical standard of Finasteride. This product is intended for research and analytical applications. Finasteride (MK-906) is a potent and competitive 5α-reductase inhibitor, with an IC50 of 4.2 nM for type II 5α-reductase. Finasteride has approximately a 100-fold greater affinity for type II 5α-reductase enzyme than for the type I enzyme. Finasteride can be used for the research of benign prostatic hyperplasia (BPH) and androgenic alopecia .
    Finasteride (Standard)
  • HY-106174
    Lapisteride

    CS 891

    		 5 alpha Reductase Endocrinology
    Lapisteride (CS 891) is an orally active 5α-reductase inhibitor. Lapisteride can inhibit 5α-reductaseactivity in the hair follicles (HF). Lapisteride can be used in prostatic hyperplasia and androgenic alopecia research .
    Lapisteride
  • HY-B0391A
    Naftopidil dihydrochloride

    KT-611 dihydrochloride; BM-15275 dihydrochloride

    		 Adrenergic Receptor Cancer
    Naftopidil dihydrochloride (KT-611 dihydrochloride) is a selective alpha1-adrenoceptor antagonist, with Kis of 3.7 nM, 20 nM and 1.2 nM for the cloned human α1a-, α1b- and α1d-adrenoceptor subtypes, respectively. Naftopidil dihydrochloride has antiproliferative effects. Naftopidil dihydrochloride can be used for the research of prostate hyperplasia .
    Naftopidil dihydrochloride
  • HY-123323
    MK-0434

    		5 alpha Reductase Endocrinology
    MK-0434 is an orally active steroid 5α-reductase inhibitor. MK-0434 specifically inhibits steroid 5α-reductase, thereby reducing the level of dihydrotestosterone (DHT) in the body. MK-0434 can be used in the study of benign prostatic hyperplasia .
    MK-0434
  • HY-19268
    GG-818

    GW 1818

    		 Adrenergic Receptor Metabolic Disease
    GG-818 (GW 1818) is a potent and selective α1 adrenoceptor antagonist, with pKi values of 9.7 for α1a, 7.8 for α1b, and 7.6 for α1d. GG-818 (GW 1818) can be used for benign prostatic hyperplasia research .
    GG-818
  • HY-165478
    FCE 28260

    		5 alpha Reductase Endocrinology
    FCE 28260 is an orally active 4-azacyclic 5α-reductase (5αR) inhibitor. FCE 28260 exhibits IC₅₀ values for human 5αR type 1 and 5αR type 2 of 36 and 3.3 nM, respectively, and for human and rat prostates with IC₅₀ values of 16 and 15 nM, respectively. FCE 28260 simultaneously blocks the production of dihydrotestosterone (DHT) in the prostate and peripheral tissues. FCE 28260 can significantly inhibit the induction of prostatic and seminal vesicle hyperplasia by testosterone (T) in rat models, without inhibiting the growth of the prostate in DHT implantation models. FCE 28260 can be used for the studies DHT-dependent diseases such as benign prostatic hyperplasia (BPH) .
    FCE 28260
  • HY-106614
    Osaterone acetate

    		Androgen Receptor 5 alpha Reductase Endocrinology
    Osaterone acetate is an orally active steroid anti-androgen agent, mainly used for benign prostatic hyperplasia (BPH) in dogs. Osaterone acetate competitively antagonizes androgen receptor and inhibits 5α-reductase, reducing the concentration of dihydrotestosterone (DHT) while blocking the growth-stimulating effects of testosterone and DHT on prostate cells. Osaterone acetate can rapidly alleviate the symptoms of BPH in dogs without affecting the fertility of breeding dogs .
    Osaterone acetate
  • HY-105173
    Teverelix

    EP 24332

    		 GnRH Receptor Histamine Receptor Endocrinology Cancer
    Teverelix (EP 24332) is a GnRH antagonist. Teverelix binds competitively and reversibly to GnRH receptors, thereby suppressing the release of LH and FSH. Teverelix can be used in the research of prostatic hyperplasia, endometriosis, and prostate cancer .
    Teverelix
  • HY-19144
    ONO-3805

    		5 alpha Reductase Others
    ONO-3805 is an early lead compound of a non-steroidal 5α-reductase inhibitor, used to inhibit the conversion of testosterone to dihydrotestosterone, with potential effects in inhibiting benign prostatic hyperplasia.
    ONO-3805
  • HY-B0192AR
    Alfuzosin hydrochloride (Standard)

    SL 77499-10 (Standard)

    		 Reference Standards Adrenergic Receptor Endocrinology
    Alfuzosin (hydrochloride) (Standard) is the analytical standard of Alfuzosin (hydrochloride). This product is intended for research and analytical applications. Alfuzosin (SL 77499-10) hydrochloride is an orally active, selective and competitive α1-adrenoceptor antagonist. Alfuzosin hydrochloride relaxes the muscles of the prostate and bladder neck, aiding in urination. Alfuzosin hydrochloride can be used in study of benign prostatic hyperplasia (BPH) .
    Alfuzosin hydrochloride (Standard)
  • HY-106363
    MK-0963

    L 654066

    		 5 alpha Reductase Others
    MK-0963 is a steroidal 5α-reductase inhibitor. MK-0963 reduces serum dihydrotestosterone (DHT) concentrations in a dose-dependent manner. MK-0963 can be used for the study of dihydrotestosterone-related diseases such as benign prostate hyperplasia (BPH) .
    MK-0963
  • HY-B0661AS1
    Tamsulosin-d4 hydrochloride

    (R)-(-)-YM12617-d4; LY253351-d4

    		 Isotope-Labeled Compounds Adrenergic Receptor Endogenous Metabolite Neurological Disease Endocrinology
    Tamsulosin-d4 (hydrochloride) is deuterium labeled Tamsulosin (hydrochloride). Tamsulosin hydrochloride ((R)-(-)-YM12617) is an inhibitor of α1-adrenergic receptor. Tamsulosin hydrochloride is used for the research of prostatic hyperplasia. Tamsulosin hydrochloride attenuates abdominal aortic aneurysm growth in animal models .
    Tamsulosin-d4 hydrochloride
  • HY-17019
    SL-89.0591

    		Adrenergic Receptor Inflammation/Immunology
    SL-89.0591 is a uroselective α1-adrenoceptor antagonist. SL-89.0591 exhibits a more potent blocking effect on urethral receptors than on vascular receptors in anesthetized rabbits, with a lower risk of orthostatic hypotension. SL-89.0591 can be used in research related to benign prostatic hyperplasia .
    SL-89.0591
  • HY-P1442
    AdTx1

    		Adrenergic Receptor Cancer
    AdTx1 is a selective α1A-adrenoceptor antagonist (Ki: 0.35 nM). AdTx1 can be used for research of benign prostatic hyperplasia .
    AdTx1
  • HY-134632
    Dehydro silodosin

    KMD-3241

    		 Adrenergic Receptor Cancer
    Dehydro silodosin (KMD-3241) is a selective α1A-adrenoceptor antagonist used in the study of benign prostatic hyperplasia .
    Dehydro silodosin
  • HY-103202
    SNAP5089 hydrochloride

    		Adrenergic Receptor Cardiovascular Disease
    SNAP5089 (hydrochloride) is a selective α1A adrenergic receptor antagonist. SNAP5089 (hydrochloride) can be used in the research of hypertension and benign prostatic hyperplasia .
    SNAP5089 hydrochloride
  • HY-105537
    Ro 70‐0004

    RS-100975

    		 Adrenergic Receptor Endocrinology
    Ro 70-0004 (RS-100975) is a selective alpha1A-adrenoceptor antagonist with a pKi of 8.9. Ro 70‐0004 can be used in the study of prostatic hyperplasia .
    Ro 70‐0004
  • HY-101826A
    ER21355 hydrochloride

    		Phosphodiesterase (PDE) Cancer
    ER21355 hydrochloride is the hydrochloride form of ER21355 (HY-101826). ER21355 hydrochloride is an inhibitor for phosphodiesterase (PDE), which is potent for ameliorating benign prostatic hyperplasia (BPH) and prostatism through increasing levels of cAMP and cGMP, and resulting a relaxation of the smooth muscle cell .
    ER21355 hydrochloride
  • HY-P3501A
    Fexapotide TFA

    NX-1207 TFA

    		 Apoptosis Cancer
    Fexapotide (NX-1207) TFA induces apoptosis selectively, reducing prostate volume at a cellular level. Fexapotide can be used in lower urinary tract symptoms (LUTS) and benign prostatic hyperplasia (BPH) research .
    Fexapotide TFA
  • HY-B0391B
    Naftopidil hydrochloride

    KT-611 hydrochloride; BM-15275 hydrochloride

    		 Adrenergic Receptor Cancer
    Naftopidil hydrochloride (KT-611 hydrochloride) is a selective alpha1-adrenoceptor antagonist, with Kis of 3.7 nM, 20 nM and 1.2 nM for the cloned human α1a-, α1b- and α1d-adrenoceptor subtypes, respectively. Naftopidil hydrochloride has antiproliferative effects. Naftopidil hydrochloride can be used for the research of prostate hyperplasia .
    Naftopidil hydrochloride
  • HY-B0391R
    Naftopidil (Standard)

    KT-611 (Standard); BM-15275 (Standard)

    		 Reference Standards Adrenergic Receptor Cardiovascular Disease Endocrinology
    Naftopidil (Standard) is the analytical standard of Naftopidil. This product is intended for research and analytical applications. Naftopidil (KT-611) is is a selective alpha1-adrenoceptor antagonist, with Kis of 3.7 nM, 20 nM and 1.2 nM for the cloned human α1a-, α1b- and α1d-adrenoceptor subtypes, respectively. Naftopidil has antiproliferative effects. Naftopidil can be used for the research of prostate hyperplasia .
    Naftopidil (Standard)
  • HY-135473
    Chlormadinone

    		Androgen Receptor Metabolic Disease Endocrinology Cancer
    Chlormadinone is an orally active anti-androgen agent. Chlormadinone improves intermittency, terminal dribbling, and urinary stream size and force. Chlormadinone can be used for the research of benign prostatic hyperplasia .
    Chlormadinone
  • HY-B0661R
    Tamsulosin (Standard)

    (R)-(-)-YM12617 free base (Standard); LY253351 free base (Standard)

    		 Reference Standards Adrenergic Receptor Endogenous Metabolite Neurological Disease Endocrinology Cancer
    Tamsulosin (Standard) is the analytical standard of Tamsulosin. This product is intended for research and analytical applications. Tamsulosin ((R)-(-)-YM12617 free base) is an inhibitor of α1-adrenergic receptor. Tamsulosin is used for the research of prostatic hyperplasia. Tamsulosin attenuates abdominal aortic aneurysm growth in animal models .
    Tamsulosin (Standard)
  • HY-116379
    RS-100329

    		Adrenergic Receptor Metabolic Disease
    RS-100329 is an α1-adrenergic receptor (α1-AR) antagonist that effectively inhibits α1-adrenergic receptor-mediated contractions of lower urinary tract tissues in vitro and in vivo. RS-100329 can be used in the research of symptoms related to benign prostatic hyperplasia .
    RS-100329
  • HY-B0371FR
    Terazosin hydrochloride (Standard)

    		Reference Standards Adrenergic Receptor Cardiovascular Disease Metabolic Disease Endocrinology
    Terazosin (hydrochloride) (Standard) is the analytical standard of Terazosin (hydrochloride). This product is intended for research and analytical applications. Terazosin hydrochloride is a quinazoline derivative and a competitive and orally active α1-adrenoceptor antagonist. Terazosin hydrochloride works by relaxing blood vessels and the opening of the bladder. Terazosin hydrochloride has the potential for benign prostatic hyperplasia (BPH) and high blood pressure treatment .
    Terazosin hydrochloride (Standard)
  • HY-B0371AR
    Terazosin hydrochloride dihydrate (Standard)

    		Reference Standards Adrenergic Receptor Metabolic Disease Endocrinology
    Terazosin (hydrochloride dihydrate) (Standard) is the analytical standard of Terazosin (hydrochloride dihydrate). This product is intended for research and analytical applications. Terazosin hydrochloride dihydrate is a quinazoline derivative and a competitive and orally active α1-adrenoceptor antagonist. Terazosin hydrochloride dihydrate works by relaxing blood vessels and the opening of the bladder. Terazosin hydrochloride dihydrate has the potential for benign prostatic hyperplasia (BPH) and high blood pressure treatment .
    Terazosin hydrochloride dihydrate (Standard)
  • HY-135473S
    Chlormadinone-d6

    		Isotope-Labeled Compounds Androgen Receptor Metabolic Disease
    Chlormadinone-d6 is the deuterium labeled Chlormadinone (HY-135473). Chlormadinone is an orally active anti-androgen agent. Chlormadinone improves intermittency, terminal dribbling, and urinary stream size and force. Chlormadinone can be used for the research of benign prostatic hyperplasia .
    Chlormadinone-d6
  • HY-107385R
    Epristeride (Standard)

    ONO-9302 (Standard); SKF105657 (Standard)

    		 Reference Standards 5 alpha Reductase Cancer
    Epristeride (Standard) is the analytical standard of Epristeride. This product is intended for research and analytical applications. Epristeride (ONO-9302) is a selective, specific and orally active uncompetitive inhibitor of human steroid 5 alpha-reductase isoform 2. Epristeride has inhibitory effects for SR isoenzymes types 2 with Ki value of 0.7-2 nM. Epristeride can be used for the research of prostatic hyperplasia and acne .
    Epristeride (Standard)
  • HY-135473R
    Chlormadinone (Standard)

    		Androgen Receptor Reference Standards Metabolic Disease
    Chlormadinone (Standard) is the analytical standard of Chlormadinone (HY-135473). This product is intended for research and analytical applications. Chlormadinone is an orally active anti-androgen agent. Chlormadinone improves intermittency, terminal dribbling, and urinary stream size and force. Chlormadinone can be used for the research of benign prostatic hyperplasia .
    Chlormadinone (Standard)

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: